-+ 0.00%
-+ 0.00%
-+ 0.00%

Piper Sandler Maintains Overweight on NeoGenomics, Raises Price Target to $13

Benzinga·02/24/2026 16:33:08
Listen to the news
Piper Sandler analyst David Westenberg maintains NeoGenomics (NASDAQ:NEO) with a Overweight and raises the price target from $12 to $13.